Evidence for metabolism of fluoromethyl 2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A), a sevoflurane degradation product, by cysteine conjugate β-lyase

Chemical Research in Toxicology

Volumn 9, Issue 4, 1996, Pages 696-702

  Spracklin, Douglas K ^a   Kharasch, Evan D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALIA; TRIFLUORO;

AMINOOXYACETIC ACID; CYSTEINE CONJUGATE BETA LYASE; DIAZOMETHANE; DRUG METABOLITE; ETHER DERIVATIVE; PROPIONIC ACID DERIVATIVE; SEVOFLURANE; TOXIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG DEGRADATION; DRUG METABOLISM; DRUG TRANSFORMATION; DRUG URINE LEVEL; GAS CHROMATOGRAPHY; GLUTATHIONE METABOLISM; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MASS SPECTROMETRY; NEPHROTOXICITY; NONHUMAN; RAT;

AMINOOXYACETIC ACID; ANESTHETICS, INHALATION; ANIMALS; CARBON-SULFUR LYASES; ENZYME INHIBITORS; ETHERS; FLUORINE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; HYDROCARBONS, FLUORINATED; INJECTIONS, INTRAPERITONEAL; KIDNEY; LYASES; MAGNETIC RESONANCE SPECTROSCOPY; MALE; METHYL ETHERS; PROPIONATES; RATS; RATS, INBRED F344;

EID: 0029894025     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx9502103     Document Type: Article

References (29)

1. Wallin, R. F., Regan, B. M., Napoli, M. D., and Stern, I. J. (1975) Sevoflurane: A new inhalational anesthetic agent. Anesth. Analg. 54, 758-766.
2. Hanaki, C., Fujii, K., Morio, M., and Tashima, T. (1987) Decomposition of sevoflurane by soda lime. Hiroshima J. Med. Sci. 36, 61-67.
3. Bito, H., and Ikeda, K. (1996) Renal and hepatic function in surgical patients after low-flow sevoflurane or isoflurane anesthesia. Anesth. Analg. 82, 173-176.
4. 2 absorbants during low-flow anesthesia in surgical patients. Anesthesiology 77, 1064-1069.
5. Morio, M., Fujii, K., Satoh, N., Imai, M., Kawakami, U., Mizuno, T., Kawai, Y., Ogasawara, Y., Tamura, T., Negishi, A., Kumagai, Y., and Kawai, T. (1992) Reaction of sevoflurane and its degradation products with soda lime. Toxicity of the byproducts. Anesthesiology 77, 1155-1164.
6. Gonsowski, C. T., Laster, M. J., Eger, E. I., II, Ferrell, L. D., and Kerschmann, R. L. (1994) Toxicity of compound A in rats. Effect of increasing duration of administration. Anesthesiology 80, 566-573.
7. Gonsowski, C. T., Laster, M. J., Eger, E. I., II, Ferrell, L. D., and Kerschmann, R. L. (1994) Toxicity of compound A in rats. Effect of a 3-hour administration. Anesthesiology 80, 556-565.
8. Keller, K. A., Callan, C., Prokocimer, P., Delgado-Herrera, M. S., Friedman, M. B., Hoffman, G. M., Wooding, W. L., Cusick, P. K., and Krasula, R. W. (1995) Inhalation toxicology study of a haloalkene degradant of sevoflurane, Compound A (PIFE), in Sprague-Dawley rats. Anesthesiology 83, 1220-1232.
9. Thummel, K. E., Kharasch, E. D., Podoll, T., and Kunze, K. (1993) Human liver microsomal enflurane defluorination catalyzed by cytochrome P-450 2E1. Drug Metab. Dispos. 21, 350-357.
10. Kharasch, E. D., and Thummel, K. E. (1993) Identification of cytochrome P450 2E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane and methoxyflurane. Anesthesiology 79, 795-807.
11. Dekant, W., Vamvakas, S., and Anders, M. W. (1994) Formation and fate of nephrotoxic and cytotoxic glutathione-S-conjugates: Cysteine conjugate β-lyase pathway. Adv. Pharmacol. 27, 115-162.
12. Kharasch, E. D., and Hankins, D. C. P450-dependent and nonenzymatic human liver microsomal defluorination of fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (Compound A), a sevoflurane degradation product. Drug Metab. Dispos., in press.
13. Jin, L., Baillie, T. A., Davis, M. R., and Kharasch, E. D. (1995) Nephrotoxicity of sevoflurane compound A [fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether] in rats: Evidence for glutathione and cysteine conjugate formation and the role of renal cysteine conjugate β-lyase. Biochem. Biophys. Res. Commun. 210, 498-506.
14. Jin, L., Davis, M. R., Kharasch, E. D., Doss, G. A., and Baillie, T. A. (1996) Identification in rat bile of glutathione conjugates of fluoromethyl 2,2-difluoro-1-(trifluoromethyl)vinyl ether, a nephrotoxic degradate of the anesthetic agent sevoflurane. Chem. Res. Toxicol. 9, 555-561.
15. van Bladeren, P. J., Buys, W., Breimer, D. D., and van der Gen, A. (1980) The synthesis of mercapturic acids and their esters. Eur. J. Med. Chem. 15, 495-497.
16. Emsley, J. W., Phillips, L., and Wary, V. (1977) in Fluorine Coupling Constants (Emsley, J. W., Feeney, J., and Sutcliffe, L. H., Eds.) Pergamon Press, New York.
17. Commandeur, J. N. M., Stijntjes, G. L., and Vermeulen, N. P. E. (1995) Enzymes and transport systems involved in the formation and disposition of glutathione-S-conjugates. Pharmacol. Rev. 47, 271-330.
18. 19F NMR and kinetic studies of phosphorylase reconstituted with 6-fluoropyridoxal and 6-fluoropyridoxal phosphate. Biochemistry 25, 1932-1939.
19. Elfarra, A. A., Jakobson, I., and Anders, M. W. (1986) Mechanism of S-(1,2-dichlorovinyl)glutathione-induced nephrotoxicity. Biochem. Pharmacol. 35, 283-288.
20. Commandeur, J. N. M., Brakenhoff, J. P. G., de Kanter, F. J. J., and Vermeulen, N. P. E. (1988) Nephrotoxicity of mercapturic acids of three structurally related 2,2-difluoroethylenes in the rat. Indications for different bioactivation mechanisms. Biochem. Pharmacol. 37, 4495-4504.
21. Hayden, P. J., and Stevens, J. L. (1990) Cysteine conjugate toxicity, metabolism, and binding to macromolecules in isolated rat kidney mitochondria. Mol. Pharmacol. 37, 468-476.
22. Hayden, P. J., Ichimura, T., McCann, D. J., Pohl, L. R., and Stevens, J. L. (1991) Detection of cysteine conjugate metabolite adduct formation with specific mitochondrial proteins using antibodies raised against halothane metabolite adducts. J. Biol. Chem. 266, 18415-18418.
23. Hayden, P. J., Yang, Y., Ward, A. J. I., Dulik, D. M., McCann, D. J., and Stevens, J. L. (1991) Formation of difluorothionoacetyl-protein adducts by S-(1,1,2,2-tetrafluoroethyl)-L-cysteine metabolites: Nucleophilic catalysis of stable lysyl adduct formation by histidine and tyrosine. Biochemistry 30, 5935-5943.
24. Hargus, S. J., and Anders, M. W. (1991) Immunochemical detection of covalently modified kidney proteins in S-(1,1,2,2-tetrafluoroethyl)-L-cysteine-treated rats. Biochem. Pharmacol. 42, R17-R20.
25. 19F NMR: Chlorotrifluorethene and tetrafluoroethene. Chem. Res. Toxicol. 5, 34-41.
26. Bruschi, S. A., West, K. A., Crabb, J. W., Gupta, R. S., and Stevens, J. L. (1993) Mitochondrial HSP60 (P1 protein) and a HSP70-like protein (mortalin) are major targets for modification during S-(1,1,2,2-tetrafluoroethyl)-L-cysteine-induced nephrotoxicity. J. Biol. Chem. 268, 23157-23161.
27. Fisher, M. B., Hayden, P. J., Bruschi, S. A., Dulik, D. M., Yang, Y., Ward, A. J. I., and Stevens, J. L. (1993) Formation, characterization, and immunoreactivity of lysine thioamide adducts from fluorinated nephrotoxic cysteine conjugates in vitro and in vivo. Chem. Res. Toxicol. 6, 223-230.
28. Martin, J. L., Dodge, M. L., and Pohl, L. R. (1994) Immunochemical detection of covalently modified kidney proteins in rats treated with the sevoflurane degradation product, Compound A (sevoolefin). Anesthesiology 81, A436.
29. Anders, M. W. (1995) Mitochondrial bioactivation of cysteine S-conjugates and 4-thiaalkanoates: Implications for mitochondrial dysfunction and mitochondrial diseases. Biochim. Biophys. Acta 1271, 51-57.